Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/annual-reviews/engineering-antibodies-for-cancer-therapy-h03n4a7Dji
- Publisher
- Annual Reviews
- Copyright
- Copyright © 2011 by Annual Reviews. All rights reserved
- ISSN
- 1947-5438
- eISSN
- 1947-5446
- DOI
- 10.1146/annurev-chembioeng-061010-114142
- pmid
- 22432610
- Publisher site
- See Article on Publisher Site
Abstract
The advent of modern antibody engineering has led to numerous successes in the application of these proteins for cancer therapy in the 13 years since the first Food and Drug Administration approval, which has stimulated active interest in developing more and better drugs based on these molecules. A wide range of tools for discovering and engineering antibodies has been brought to bear on this challenge in the past two decades. Here, we summarize mechanisms of monoclonal antibody therapeutic activity, challenges to effective antibody-based treatment, existing technologies for antibody engineering, and current concepts for engineering new antibody formats and antibody alternatives as next generation biopharmaceuticals for cancer treatment.
Journal
Annual Review of Chemical and Biomolecular Engineering – Annual Reviews
Published: Jul 15, 2011